Find in Library

TPD52L1-ROS1 Rearrangement as a New Acquired Resistance Mechanism to Osimertinib That Responds to Crizotinib in Combination With Osimertinib in Lung Adenocarcinoma

oleh: Caihua Xu, MD, Dapeng Li, MD, Weiming Duan, MD, Min Tao, PhD